Finotonlimab A China IO Latecomer But First In Country For 1L HNSCC

SinoCellTech's PD-1 inhibitor finotonlimab has become the first immuno-oncology drug to be approved in China for first-line head and neck squamous cell carcinoma regardless of PD-L1 expression.